Omnicell, Inc. Files 8-K: Board & Compensation Updates
Ticker: OMCL · Form: 8-K · Filed: Sep 25, 2024 · CIK: 926326
| Field | Detail |
|---|---|
| Company | Omnicell, Inc. (OMCL) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $645,000, $161,250, $2,250,000, $1,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
Related Tickers: OMCL
TL;DR
Omnicell filed an 8-K on 9/25/24 detailing board changes and executive compensation updates.
AI Summary
Omnicell, Inc. filed an 8-K on September 25, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate governance and financial reporting activities for the company.
Why It Matters
This filing provides insight into the company's leadership structure and executive pay, which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing primarily concerns corporate governance and executive compensation, which are standard disclosures and do not inherently indicate significant new risks.
Key Players & Entities
- OMNICELL, INC. (company) — Registrant
- September 25, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors" as an item information, suggesting changes to the board, but the specific details are not provided in this excerpt.
What are the key aspects of the compensatory arrangements of certain officers?
The filing lists "Compensatory Arrangements of Certain Officers" as an item information, indicating that details regarding executive compensation are included, but the specifics are not detailed in this excerpt.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is September 25, 2024.
What is Omnicell, Inc.'s state of incorporation?
Omnicell, Inc. is incorporated in Delaware.
What is Omnicell, Inc.'s IRS Employer Identification Number?
Omnicell, Inc.'s IRS Employer Identification Number is 94-3166458.
Filing Stats: 1,202 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-09-25 16:10:53
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value OMCL NASDAQ Global Select M
- $645,000 — ompensated at an initial base salary of $645,000 per annum and will be eligible for a sp
- $161,250 — rth quarter cash bonus with a target of $161,250 subject to achieving certain onboarding
- $2,250,000 — ith a grant date value of approximately $2,250,000 in the form of restricted stock units (
- $1,500,000 — ith a grant date value of approximately $1,500,000, 25% of which will vest following the o
Filing Documents
- tm2424506d1_8k.htm (8-K) — 30KB
- tm2424506d1_ex99-1.htm (EX-99.1) — 14KB
- tm2424506d1_ex99-1img001.jpg (GRAPHIC) — 18KB
- 0001104659-24-102781.txt ( ) — 246KB
- omcl-20240925.xsd (EX-101.SCH) — 3KB
- omcl-20240925_lab.xml (EX-101.LAB) — 33KB
- omcl-20240925_pre.xml (EX-101.PRE) — 22KB
- tm2424506d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 25, 2024, Omnicell, Inc. ("Omnicell" or the "Company") announced that Nnamdi Njoku, age 48, has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. A press release announcing the appointment of Omnicell's Executive Vice President and Chief Operating Officer is attached as Exhibit 99.1 hereto and incorporated herein by reference. Prior to joining Omnicell, Mr. Njoku served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc., a global medical technology leader, from March 2023 to September 2024. From April 2022 to March 2023, Mr. Njoku served as Senior Vice President & President – Neuromodulation at Medtronic, Inc., a subsidiary of Medtronic plc, a leading global healthcare technology company ("Medtronic"). Prior to that, he served as President - Mechanical Circulatory Support from August 2019 to March 2022, as Vice President & General Manager – Transformative Solutions from February 2018 to August 2019 and as Vice President, Surgical Synergy from September 2017 – October 2018 at Medtronic. From August 2005 to August 2017, Mr. Njoku held executive operational roles of increasing responsibility at Medtronic. Prior to Medtronic, Mr. Njoku served in operational roles of increasing responsibility at UnitedHealth Group and Deloitte Consulting. Mr. Njoku received a Bachelor of Arts degree in business administration from the University of St. Thomas, and an MBA from Cornell University. There are no arrangements or understandings between Mr. Njoku and any other persons pursuant to which Mr. Njoku was appointed as an executive officer of the Company. There are no family relationships between Mr. Njoku and any director or executive officer of the Company. There are not any transaction
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release entitled "Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer" dated September 25, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. OMNICELL, INC. Date: September 25, 2024 /s/ Corey J. Manley Corey J. Manley Executive Vice President and Chief Legal and Administrative Officer